EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Longitudinal single-cell analysis of glucagon-like peptide-2 treatment in patients with short bowel syndrome

Yumi Kudo, Kentaro Miyamoto, Shohei Suzuki, Akihiko Chida, Anna Tojo, Mai Hasegawa, Arina Shigehara, Ikuko Koya, Yoshinari Ando, Masayasu Sato, Aya Kondo, Tomoko Kumagai und 22 weitere

JCI Insight · 23.09.2025 · 10 (20)

DOI: 10.1172/jci.insight.194497 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCI Insight, online erschienen am 07.08.2025. Verfasst von Yumi Kudo und 33 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Surgery, and. Hauptthemen laut MEDLINE: Short Bowel Syndrome, Glucagon-Like Peptide 2, Peptides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Glucagon-like peptide-2 (GLP-2) analogs are used clinically to enhance nutrient absorption in patients with short bowel syndrome (SBS); however, the precise mechanism remains unclear. To address this, the study aimed to clarify the dynamics of intestinal epithelial cells and immune cells in patients with SBS treated with GLP-2 analogs. METHODS Five male patients diagnosed with SBS, all of whom received treatment with the GLP-2 analog teduglutide, were included in the study. We conducted longitudinal single-cell RNA sequencing (scRNA-Seq) analysis of intestinal tissue from patients with SBS over a year, integrating microbiome composition analysis. RESULTS After treatment, the α-diversity of the gut microbiome increased, indicating a more varied microbial environment. ScRNA-Seq analysis revealed a reduction of T helper 2 cells and an increase in regulatory T cells, suggesting a shift toward an immunoregulatory intestinal environment. Additionally, nutrient-absorbing enterocyte-Top2 and middle clusters expanded, enhancing the absorption capacity, whereas major histocompatibility complex class I/II–expressing enterocyte-Top1 cells declined, potentially modulating immune responses. CONCLUSION The study findings indicate that GLP-2 analogs reshape intestinal immunity and microbiota, fostering a less inflammatory environment while promoting nutrient uptake efficiency. These insights offer a deeper understanding of the role of GLP-2 analogs in gut adaptation and provide a foundation for refining clinical strategies for SBS treatment. FUNDING This work was supported by Sakaguchi Memorial Foundation, Grants-in-Aid from the Japanese Society for the Promotion of Science (JSPS) (21K18272, 23H03665, 23H02899, 23K27590, 25K22627, 23K08037), JST FOREST(21457195), and the Takeda Japan Medical Office Funded Research Grant 2022.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Short Bowel SyndromeGlucagon-Like Peptide 2PeptidesHumansMaleSingle-Cell AnalysisMiddle AgedGastrointestinal MicrobiomeAdultLongitudinal StudiesIntestinal MucosaT-Lymphocytes, RegulatoryEnterocytes

Stichwörter der Autor:innen

Clinical ResearchDrug therapyGastroenterology

Substanzen

Glucagon-Like Peptide 2teduglutidePeptides

Autor:innen und Institutionen

  • Department of Pediatric Surgery, and.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Shinanomachi, Shinjuku-ku, Tokyo, Japan.
  • Research Department, R&D Division, Miyarisan Pharmaceutical Co., Ltd., Saitama, Japan.
  • Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Shinanomachi, Shinjuku-ku, Tokyo, Japan.
  • Laboratory for Regulatory Genomics, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan.
  • Department of Pediatric Surgery, Tokyo Metropolitan Children's Medical Center, Fuchu-shi, Tokyo, Japan.

Zitieren

APA

Kudo, Y., Miyamoto, K., Suzuki, S., Chida, A., Tojo, A., Hasegawa, M., Shigehara, A., Koya, I., Ando, Y., Sato, M., Kondo, A., Kumagai, T., Deguchi, H., Sugiyama, Y., Ito, Y., Shirosaki, K., Yamagishi, S., Maeda, Y., Kanamori, H., …, & Sujino, T. (2025). Longitudinal single-cell analysis of glucagon-like peptide-2 treatment in patients with short bowel syndrome. JCI Insight, 10(20). https://doi.org/10.1172/jci.insight.194497

Vancouver

Kudo Y, Miyamoto K, Suzuki S, Chida A, Tojo A, Hasegawa M, et al. Longitudinal single-cell analysis of glucagon-like peptide-2 treatment in patients with short bowel syndrome. JCI Insight. 2025;10(20). doi:10.1172/jci.insight.194497

BibTeX
@article{Kudo2025,
  author = {Kudo, Yumi and Miyamoto, Kentaro and Suzuki, Shohei and Chida, Akihiko and Tojo, Anna and Hasegawa, Mai and Shigehara, Arina and Koya, Ikuko and Ando, Yoshinari and Sato, Masayasu and Kondo, Aya and Kumagai, Tomoko and Deguchi, Harunori and Sugiyama, Yoshiki and Ito, Yoko and Shirosaki, Koji and Yamagishi, Satoko and Maeda, Yutaro and Kanamori, Hiroki and Kano, Motohiro and Kato, Mototoshi and Tsujikawa, Hanako and Yoshimatsu, Yusuke and Takabayashi, Kaoru and Okabayashi, Koji and Kanai, Takanori and Hosoe, Naoki and Kato, Motohiko and Moody, Jonathan and Hon, Chung-Chau and Kuroda, Tatsuo and Yamada, Yohei and Fujino, Akihiro and Sujino, Tomohisa},
  title = {Longitudinal single-cell analysis of glucagon-like peptide-2 treatment in patients with short bowel syndrome},
  journal = {JCI Insight},
  year = {2025},
  volume = {10},
  number = {20},
  doi = {10.1172/jci.insight.194497}
}
Kostenlos starten →